Valsartan
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Valsartan and local guidelines before prescribing.
Angiotensin II receptor blocker
Mechanism
Angiotensin II receptor blocker.
Uses
Hypertension, heart failure, post-MI.
Dosing
- Sacubitril/valsartan | 24/26 mg or 49/51 mg twice daily initially; target 97/103 mg twice daily.
Cardiology: Heart Failure › 2.33 💊 Common Drugs and Adult Doses - Sacubitril/valsartan | HFrEF: 24/26 mg or 49/51 mg twice daily, titrated to 97/103 mg twice daily; stop ACE inhibitor at least 36 hours before.
Cardiology: Cardiomyopathies › 3.54 Common Adult Drugs and Doses
Side effects
Dizziness, hyperkalaemia, renal impairment, angioedema rare.
Interactions
NSAIDs, potassium-sparing diuretics, ACE inhibitors, lithium.
Contraindications and cautions
Pregnancy, bilateral renal artery stenosis
Monitoring
U&E
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Caution in severe renal or hepatic impairment
Overdose and reversal
Supportive
Special advice
U&E after starting; avoid in pregnancy; used with sacubitril in heart failure (never with ACE inhibitor).
More from the textbook: uses, cautions and other points
- Angiotensin receptor blockers (ARBs) (losartan, candesartan, valsartan) - block the AT1 receptor; same uses; no cough (used when ACE inhibitors cause it); angioedema much less common.
Cardiology: Anatomy Physiology and Pharmacology - Sacubitril/valsartan | ARNI for HFrEF; 36-hour gap after ACE inhibitor.
Cardiology: Anatomy Physiology and Pharmacology - Sacubitril/valsartan raises BNP (it blocks its breakdown) - use NT-proBNP to monitor.
Cardiology Investigations - Full heart failure therapy for reduced EF: ACE inhibitor/ARB or sacubitril/valsartan, beta blocker, MRA and SGLT2 inhibitor, plus diuretics for congestion.
Cardiology: Ischaemic Heart Disease (ACS) › 1.30 Pericarditis and Late Complications - Optimise heart failure therapy first: ACE inhibitor or sacubitril/valsartan, beta blocker, MRA, SGLT2 inhibitor, and diuretics.
Cardiology: Valvular heart disease › 4.22 Secondary MR - … function, potassium, frailty and clinical stability. If symptoms persist despite maximally tolerated treatment, consider switching the ACE inhibitor to sacubitril/valsartan. When ACE inhibitor intolerance other than angioedema occurs, NICE supports using an ARNI with the other foundational classes. If ACE inhibitor-associated …
Cardiology: Heart Failure › 2.17 💊 Chronic HFrEF - The Four Foundational Drug Classes
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (3 mentions)
- Cardiology Investigations (1 mention)
- Cardiology: Ischaemic Heart Disease (ACS) (1 mention)
- Cardiology: Valvular heart disease (1 mention)
- Cardiology: Heart Failure (8 mentions)
- Cardiology: Cardiomyopathies (4 mentions)
- Respiratory: Emergencies (1 mention)
- Renal: Anatomy, Physiology and Pharmacology (2 mentions)
- Renal: Emergencies (1 mention)
- Dermatology: Urticaria, drug reactions, blistering, ulcers and emergencies (1 mention)
- ENT: Emergencies (1 mention)
- Clinical Immunology: Allergy, anaphylaxis, urticaria and angioedema (1 mention)
- Integrated cardiology chapter (15 mentions)
- Integrated respiratory chapter (1 mention)